Abstract:Background: Despite its effectiveness, the standard course of chemoradiation for the treatment of human papillomavirus (HPV)-related oropharyngeal carcinoma (OPC) results in considerable treatment-related adverse effects. Studies proved that HPV-positive OPC is very sensitive to radiotherapy. Using de-escalation therapy as a new strategy is critical to maintaining positive outcomes while alleviating side effects. However, some studies hold that reduced dose causes insufficient effect on tumor killing. We conducted this systematic review and meta-analysis of survival and adverse reactions in patients with HPV-related OPC by retrospective analysis and evaluated the therapeutic effect of reducing the radiation dose.Methods: Data were double-selected and extracted by searching seven electronic databases, Original studies in all language treated HPV-associated OPC with reduced-dose and standard-dose therapies were included. Overall survival (OS), progression-free survival (PFS), and incidence rates of adverse events were obtained by pooling analyses. Statistical analyses were performed using RStudio Version 1.1.383 (RStudio, Boston, MA, USA) via the Meta-Analysis R Package (metafor). Heterogeneity was evaluated using the I<sup>2</sup> statistic and the Cochran Q test. We used Stata (version 15.0) for forest graph.Results: Thirteen studies were included in this meta-analysis, involving a dose range of 66-70 Gy for the standard treatment regimen and <66 Gy for the reduced-dose group. There was no significant difference in the age of the patients in the standard and the reduced treatment groups (60.9±5.9 <i>vs</i>. 58.6±2.4 years). Nine studies were included as standard cohort and thirteen studies were enrolled as reduced-dose cohort. The 2- and 3-year overall survival rates in the reduced-dose group (95.66% and 91.51%, respectively) were superior to those in the standard-dose group (88.36% and 87.46%, respectively). There was no significant difference in PFS between the two groups. A systematic review of articles on dose reduction and the standard dose was also conducted. The most common complication in reduced-dose radiation was oral mucositis (36.4%), followed by decreased white blood cell (WBC) count (30.5%) and dry mouth (29.1%).Conclusions: Reducing the radiation dose in patients with HPV-related OPC substantially alleviates the treatment toxicities and optimizes the quality of life of patients while at the same time maintaining favorable oncologic outcomes.

Treatment strategy for HPV-positive oropharyngeal cancer: a literature review

Can we safely de-escalate HPV + oropharyngeal cancers? – A review of current practices and novel approaches

The epidemic of human papillomavirus virus-related oropharyngeal cancer: current controversies and future questions

De-Escalation Treatment for Human Papillomavirus-Related Oropharyngeal Cancer: Questions for Practical Consideration

Rethinking treatment paradigms: Neoadjuvant therapy and de-escalation strategies in HPV-positive head and neck cancer

HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management

HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis

Personalized precision radiotherapy and its evolving role for human papillomavirus-positive oropharyngeal cancer

HPV-associated head and neck cancer: a virus-related cancer epidemic

Effectiveness of treatment of oropharyngeal carcinoma patients

DETECTION OF HUMAN PAPILLOMA VIRUS IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS: A LITERATURE REVIEW

A Review and Comparative Analysis of Transoral Surgical Treatment Versus Conservative Management in Early-Stage Oropharyngeal Cancer

The role of surgery and deescalation for HPV‐related oropharyngeal cancer

Reduced-dose radiation in human papillomavirus-associated oropharyngeal carcinoma can improve outcome: a systematic review and meta-analysis

Oral Cancer and HPV: Review Article

Moving from conventional to adaptive risk stratification for oropharyngeal cancer

Retrospective study of survival in human papillomavirus-negative oropharyngeal squamous cell carcinoma treated with primary surgery and associated prognostic factors.

Clinical prognostic factors to guide treatment strategy for HPV‐positive oropharyngeal cancer using treatment outcomes of induction chemotherapy: A real‐world experience

The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer

[Surgical Treatment of Oropharyngeal Cancer - Recommendations of the Current German S3 Guideline, Part I]

Evolution of a Paradigm Switch in Diagnosis and Treatment of HPV-Driven Head and Neck Cancer-Striking the Balance Between Toxicity and Cure